After a rocky couple of years, Hong Kong has defied its sceptics and definitively bounced back. As Asia’s financial capital and the bridge between mainland China and international markets, the global stock market slump between 2021 and 2024 had an outsized impact on Hong Kong, with sluggish GDP growth and decreased listing activity on the Hong Kong Stock Exchange. This challenging period was accompanied with massive initial investments into the “innovation and technology” field, as the city attempts a generational pivot beyond its traditional sphere of finance.
The teething pains that Hong Kong was feeling during these transition years were, however, built into a grander long-term vision. Specifically, China’s 14th Five-Year Plan (2021-2025) outlined an important role for Hong Kong, not only as a capital market but also as a hub for research and manufacturing at the bleeding edge of artificial intelligence, aerospace, and life sciences, among other fields. The Plan also called for greater integration between the speed and scale available in the Greater Bay Area (the giant swathe of southern mainland China that borders Hong Kong and Macao) and the deep-rooted expertise available in Hong Kong
“We have long been a trusted gateway for two-way trade and investment. But we can do more. We can contribute to the country’s efforts in building a modernised industrial system and advance technological innovation, accelerating our rise as an international innovation and technology hub.”
Paul Chan, secretary of finance
Already, the tide seems to have turned with economic growth of 3.5 percent for 2025, well ahead of developed Asian economies like Korea and Japan (one percent), as well as the USA (two percent), and the European Union (1.5 percent). Similar growth rates are expected for 2026, and there is, once again, a feeling of buoyancy and optimism among Hong Kong’s dense patchwork of skyscrapers, trams, bridges and ferries, with capital and people flowing back into the city.
On the financial markets, the Hang Seng Index – the primary benchmark for the Hong Kong stock market – rose by an astonishing 28 percent over the course of 2025, trading close to USD 250 billion a day at its height. Meanwhile, initial public offerings (IPOs) in Hong Kong reached USD 280 billion last year, the most of any market in the world.
This story is especially pronounced in the biotech space. China’s biotechs have become incredibly hot property (Chinese-originated assets now account for over 50 percent of total global biotech M&A and licensing value), with many choosing Hong Kong as their listing destination. The Hang Seng Biotech Index was up 64.5 percent last year and HKEX is now outperforming NASDAQ as the premier global biotech listing destination.
The city’s long-term bets on innovation – especially in niches like AI-driven drug discovery and robotics – appear to be paying off. For instance, Insilico Medicine – sponsor of the first drug discovered and designed entirely by generative AI to reach human trials – raised USD 292 million in a heavily oversubscribed HKEX IPO in December 2025. The company, dual-headquartered in Hong Kong and Boston, has since struck a major R&D deal with Eli Lilly, potentially rising to USD 2.75 billion in value.
“Hong Kong’s future development model is increasingly described as a ‘north-south dual engine.’ The southern part of the city, particularly Hong Kong Island and the Central district, will continue to serve as the financial centre, while the northern region is being developed as a new hub for innovation and technology.”
Peter Yan, director general, Office for Attracting Strategic Enterprises (OASES)
Beyond this financial rebound, the physical landscape of the city itself is transforming. Most significantly, the 2026 Budget included billion-dollar-plus funding boosts for the so-called ‘Northern Metropolis.’ A vast swathe of previously unused land that juts up against the mainland city of Shenzhen, the idea is for this area to become a high-tech research and manufacturing hub, with increased flows of data, products, and people between the two sides of the border.
Meanwhile, Hong Kong is hoping to leverage greater connectivity with the rest of its region to attract a greater proportion of the global clinical research pipeline, especially in niche and specialised fields such as rare diseases and cell and gene therapies. ‘Made in Hong Kong’ CAR-T is already a reality, with an investigative Phase I trial for solid tumours underway at the Hong Kong Institute of Biotechnology, while major international names are also moving in. Roche’s recent trial at the Chinese University of Hong Kong is one of the first globally to recruit Chinese patients into a Phase I (first-in-human) clinical oncology trial, while GSK recently signed a wide-ranging collaboration with the University of Hong Kong for a series of real-world evidence studies.
Building on the city’s established fundamentals, a newly established Greater Bay Area Clinical Trial Institute (GBAICTI) aims to unite a fragmented system and provide a dedicated single platform for trial application, conduct, and marketing authorisation processes, as well as opportunities to access the 87-million-strong GBA population.
The hope is that Hong Kong can prove a testing ground for cutting-edge innovations, as well as a place where the local population gets greater access to these same new medicines. The desire for greater domestic access to new, often expensive, therapies will, however, have to be balanced with budgetary constraints and caring for the city’s rapidly ageing population. Hong Kong’s Primary Healthcare Blueprint – launched in 2023 – provides some solutions, integrating medical and social services and leveraging private sector resources to improve the overall health of the population and reduce the burden on public hospitals.
Finally, on the regulatory front, significant updates have been made to Hong Kong’s drug regulation. The current pilot “1+” system allows drugs to be registered locally after certification by just one major reference regulatory authority (such as the FDA or EMA) instead of the previous requirement of two, reducing the registration processing time from 150 to 100 days. The city has also launched a roadmap for establishing its own independent regulator by 2030, theoretically providing faster access within Hong Kong as well as a platform for Chinese innovation to hit global markets more quickly.
“Over the past two decades, and particularly in the last ten years, Hong Kong has undergone a clear and deliberate shift. The economy has moved beyond its traditional reliance on finance, logistics, and trading towards a more focused commitment to innovation and technology.”
Terry Wong, CEO, Hong Kong Science and Technology Parks Corporation (HKSTP)
All in all then, as this new report shows, Hong Kong is in the process of reinventing itself. Still the financial hub that connects a resurgent China with the rest of the world, Hong Kong is also becoming much more than that. Doubling down on its existing strengths and branching out into new, related, fields, Hong Kong is both supporting China’s industrial transformation goals and contributing to local, regional and global health. Having displayed pragmatism, doggedness, and no little expertise to ride out the choppy waters of the past few years, the Hong Kong of 2026 is a more compelling and differentiated investment prospect than ever before.
